Fibromyalgia Clinical Trial
Official title:
Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia
Verified date | May 2007 |
Source | McGill University Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
Most chronic pain patients with insomnia are currently not well-managed using existing
medications. If found to safely improve sleep with chronic pain patients, nabilone could be
added to the treatment options available in the management of fibromyalgia and associated
symptoms.
The principle hypothesis of this study is that nabilone at a dose of 0.5-1mg is as
efficacious as amitriptyline at a dose of 10-20mg, in improving sleep quality in patients
with fibromyalgia.
Status | Completed |
Enrollment | 32 |
Est. completion date | March 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients aged =18 years; - A diagnosis of fibromyalgia according to the American College of Rheumatology classification criteria (Wolfe F, Smythe HA, et al 1990); - Suffering from self-reported disturbed sleep; - Negative urine screen for cannabinoids; - Women of childbearing potential must agree to use adequate contraception during study and for 3 months after study; - Ability to attend research centre every second week for approximately seven to nine weeks and be able to be contacted by telephone during the study period; - Stable drug regimen for 1 month prior to randomization; - Normal liver (AST <3x normal) and renal function (serum creatinine <133µmol/L); - Haematocrit >38%; - Negative serum bHCG; - Proficient in English or French; - Willing and able to give written informed consent; - Ability to follow study protocol (cognitive and situational). Exclusion Criteria: - Patients currently using cannabis or cannabinoid or tricyclic antidepressants (TCA) and who are unable to undergo a 2 week washout period before entering the study; - Pain due to cancer; - Unstable cardiac disease such as cardiac arrhythmias, cardiac failure, ischaemic heart disease and/or hypertension on clinical history and examination; - History of psychotic disorder or schizophrenia; - Known hypersensitivity to cannabinoids, amitriptyline, or related tricyclic antidepressants; - Currently taking or unable to stop taking monoamine oxidase inhibitors (a two-week washout period is necessary for subjects taking MAOIs); - History of seizures/epilepsy; - Diagnosis of glaucoma; - Urinary retention; - Pregnancy and/or breast-feeding; - Participation in other clinical trial in the 30 days prior to randomization; - A recent manic episode (within the past year); - Current suicidal ideation or history of suicide attempts |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | McGill University Health Centre, Pain Centre | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
McGill University Health Center |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of sleep assessed using the Leeds Sleep Evaluation Questionnaire and the Insomnia Severity Index | Day 1, 15, 29 and 43 and given to the patient to complete every second day while taking the study medication | ||
Secondary | Pain Intensity using the VAS (visual analogue scale) | Days 1, 15, 29 and 43 | ||
Secondary | Pain Quality using the McGill Pain Questionnaire | Days 1, 15, 29 and 43 | ||
Secondary | Mood using the Profile of Mood States (POMS) Questionnaire | Days 1, 15, 29 and 43 | ||
Secondary | Quality of Life using the Fibromyalgia Impact Questionnaire (FIQ) | Days 1, 15, 29 and 43 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05659862 -
Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT03042728 -
Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program
|
N/A | |
Recruiting |
NCT06097091 -
Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia
|
N/A | |
Recruiting |
NCT04554784 -
Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia
|
N/A | |
Completed |
NCT03300635 -
Metabolism, Muscle Function and Psychological Factors in Fibromyalgia
|
N/A | |
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT03166995 -
Postural Exercises in Women With Fibromyalgia
|
N/A | |
Completed |
NCT03227952 -
Sensory Stimulation in Fibromyalgia
|
N/A | |
Recruiting |
NCT06237595 -
Vagus Nerve Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT01888640 -
Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
|
N/A | |
Completed |
NCT03641495 -
Pain Education and Therapeutic Exercise for Fibromyalgia
|
N/A | |
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Active, not recruiting |
NCT05128162 -
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
|
Phase 2 | |
Completed |
NCT04674878 -
Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia
|
N/A | |
Active, not recruiting |
NCT04084795 -
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
|
N/A | |
Completed |
NCT03129906 -
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
|
N/A | |
Completed |
NCT05058911 -
Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia
|
N/A | |
Recruiting |
NCT04571853 -
New Educational Tool for FM
|
N/A | |
Recruiting |
NCT04571528 -
Effectiveness of VIRTUAL FIBROWALK STUDY
|
N/A |